New scan could spot dangerous prostate cancer without needle biopsy

NCT ID NCT03471650

Ongoing Diagnosis Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a special PET/CT scan using a radioactive tracer called 18F-DCFPyL can better detect aggressive prostate cancer in men with elevated PSA levels. About 150 men with PSA between 2-10 ng/mL and no prior biopsy will receive the scan before their standard biopsy. The goal is to see if the scan is more accurate than PSA alone at identifying cancers that need treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-DCFPyL (a radioactive tracer for PET/CT imaging)
What this could lead to: If successful, this scan could become a more accurate, non-invasive way to detect aggressive prostate cancer early, reducing unnecessary biopsies.
What could go wrong: This is a single-center, phase II study with only 150 men, so results may not apply to everyone. The scan may not be better than current methods and could still miss some cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

SKCCC

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.